Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US40131M1099
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG006D97VY9
GH
Guardant Health Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Diagnostics & Research · THEMEFOLIO: $HLTH
NAME
Guardant Health Inc
ISIN
US40131M1099
TICKER
GH
MIC
XNAS
REUTERS
GH.OQ
BLOOMBERG
GH US
Tue, 03.11.2026       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the appointment of Kevin Sayer to its board of directors. Mr. Sayer is former CEO of Dexcom, Inc. and current Executive Chairman of the Dexcom board, with decades of strategic leadership experience in digital health technology. “We are excited to welcome Ke...
Read more
Guardant Health
Technical Analysis Termsheets Terminal
Permalink
Tue, 03.11.2026       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced it received the 2026 Prix Galien USA Award for Best Medical Technology for Shield™, the leading blood test for colorectal cancer (CRC) detection and first to receive FDA approval for primary CRC screening, for its achievements in expanding patient choice and increa...
Read more
Guardant Health
Technical Analysis Termsheets Terminal
Permalink
Thu, 29.10.2026       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, applauded the enactment of a new law (HB 1123) in Pennsylvania aligning insurance coverage for colorectal cancer screening to reflect the latest American Cancer Society (ACS) and National Comprehensive Cancer Center (NCCN) guidelines, ensuring no cost-sharing for about 2 mill...
Read more
Guardant Health
Technical Analysis Termsheets Terminal
Permalink
Tue, 20.10.2026       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the company and its research collaborators will present 25 abstracts—including five rapid oral presentations—demonstrating advances in methylation-based circulating tumor DNA (ctDNA) monitoring and liquid biopsy technology across lung, colorectal, and ga...
Read more
Guardant Health
Technical Analysis Termsheets Terminal
Permalink
Thu, 15.10.2026       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators presented new data showing the critical role of blood-based testing in increasing overall colorectal cancer (CRC) screening and follow-up colonoscopy adherence at the American College of Gastroenterology (ACG) 2026 A...
Read more
Guardant Health
Technical Analysis Termsheets Terminal
Permalink
Thu, 08.10.2026       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that Guardant360® CDx has received CE-marking under Europe’s in Vitro Diagnostic Medical Devices Regulation as a companion diagnostic (CDx) to identify patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer w...
Read more
Guardant Health
Technical Analysis Termsheets Terminal
Permalink
Thu, 08.10.2026       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2026 after market close on Thursday, November 5, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the web...
Read more
Guardant Health
Technical Analysis Termsheets Terminal
Permalink
Mon, 05.10.2026       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced Cancer Research Communications, a journal of the American Association for Cancer Research, has published results from the COSMOS-MEL01 study (UMIN000042040). The study is the first published prospective, multicenter evaluation of the tissue-free, epigenomic G...
Read more
Guardant Health
Technical Analysis Termsheets Terminal
Permalink
Mon, 14.09.2026       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer screening (CRC) will be covered in EviCore by Evernorth clinical guidelines effective January 1, 2027, per ACS guidelines. EviCore is a Cigna-owned company and the second largest specialty benefits manager in the c...
Read more
Guardant Health
Technical Analysis Termsheets Terminal
Permalink
Wed, 09.09.2026       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the company and its research collaborators will present 20 abstracts—including one mini oral presentation—showcasing advances in methylation-based tumor classification and liquid biopsy technology across lung cancer subtypes at the 2026 World Conference...
Read more
Guardant Health
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Tue, 08.09.2026       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it has been named to Business Insider’s America's Most Innovative Businesses 2027 list, earning the highest rating available with a five-star recognition awarded to only other 12 biotechnology research companies in the category. The inaugural Business Insid...
Read more
Guardant Health
Technical Analysis Termsheets Terminal
Permalink
Sat, 05.09.2026       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® CDx as a companion diagnostic (CDx) to identify patients with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer harboring tumors with ESR1 mutations bef...
Read more
Guardant Health
Technical Analysis Termsheets Terminal
Permalink
Tue, 01.09.2026       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer screening (CRC) will be covered in Carelon Healthcare Services clinical guidelines effective November 15. Carelon Healthcare Services is one of the largest specialty benefits managers in the country and subsidiary...
Read more
Guardant Health
Technical Analysis Termsheets Terminal
Permalink
Mon, 24.08.2026       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will appeal the final judgment from the U.S. District Court for the District of Delaware related to intellectual property claims brought against Guardant by TwinStrand Biosciences, Inc. and University of Washington, with execution of the final judgment and...
Read more
Guardant Health
Technical Analysis Termsheets Terminal
Permalink
Mon, 10.08.2026       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on July 21, 2026, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted stock units (“RSUs”) representing 46,044 shares of its common stock to 149 new non-executive employees with a grant date of August 3, 2026,...
Read more
Guardant Health
Technical Analysis Termsheets Terminal
Permalink
Thu, 30.07.2026       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended June 30, 2026. Second Quarter 2026 Financial Highlights For the three-month period ended June 30, 2026, as compared to the same period of 2025: Reported total revenue of $335.0 million, an increase of 44%, driven...
Read more
Guardant Health
Technical Analysis Termsheets Terminal
Permalink
Wed, 29.07.2026       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. Canaccord Genuity 46th Annual Growth Conference in Boston, MA Fireside chat on Wednesday, August 12th at 3:00 p.m. Eastern Time Morgan Stanley 24th Annual Global Healthcare Confer...
Read more
Guardant Health
Technical Analysis Termsheets Terminal
Permalink
Tue, 28.07.2026       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of a new video featuring actor and cancer advocate Patrick Dempsey that highlights the more than 55,000 Americans who will lose their lives to colorectal cancer (CRC) this year1, a majority of which will not have been up to date with their colorect...
Read more
Guardant Health
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.07.2026       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2026 after market close on Thursday, July 30, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webca...
Read more
Guardant Health
Technical Analysis Termsheets Terminal
Permalink
Wed, 01.07.2026       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer screening (CRC) is now covered for eligible UnitedHealth Group (UHG) members1, making it the first major commercial insurer to provide coverage for adults 45 or older amid rising CRC rates for adults under 652 and...
Read more
Guardant Health
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Thu, 11.06.2026       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® CDx as a companion diagnostic (CDx) for Boehringer Ingelheim’s HERNEXEOS® (zongertinib tablets), the first targeted therapy for adults with HER2 (ERBB2)-mutant advanced non-small cell...
Read more
Guardant Health
Technical Analysis Termsheets Terminal
Permalink
Thu, 28.05.2026       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present 38 abstracts, as well as one oral presentation in partnership with Pfizer, showcasing advances in methylation-based tumor classification and liquid biopsy technology at the American Society of Clinical O...
Read more
Guardant Health
Technical Analysis Termsheets Terminal
Permalink
Wed, 27.05.2026       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that its FDA-approved Shield™ blood test is now included in updated American Cancer Society (ACS) Colorectal Cancer (CRC) Screening Guidelines published today. The major screening guideline update recommends Shield as a choice for patients who decline or have not c...
Read more
Guardant Health
Technical Analysis Termsheets Terminal
Permalink
Wed, 20.05.2026       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® Liquid CDx, advancing blood-based comprehensive genomic testing by integrating genomic and epigenomic insights and helping clinicians make better-informed treatment selection decisions...
Read more
Guardant Health
Technical Analysis Termsheets Terminal
Permalink
Mon, 18.05.2026       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on April 21, 2026, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted stock units (“RSUs”) representing 143,898 shares of its common stock to 267 new non-executive employees with a grant date of May 11, 2026 u...
Read more
Guardant Health
Technical Analysis Termsheets Terminal
Permalink
Thu, 07.05.2026       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2026. First Quarter 2026 Financial Highlights For the three-month period ended March 31, 2026, as compared to the same period of 2025: Reported total revenue of $301.7 million, an increase of 48%, driven...
Read more
Guardant Health
Technical Analysis Termsheets Terminal
Permalink
Mon, 04.05.2026       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved the Guardant360® CDx liquid biopsy test as a companion diagnostic for VEPPANU (vepdegestrant). VEPPANU, jointly developed by Arvinas, Inc. and Pfizer Inc., is approved for the treatment of adults w...
Read more
Guardant Health
Technical Analysis Termsheets Terminal
Permalink
Thu, 30.04.2026       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a multi-year strategic collaboration with Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, to support the development and potential comme...
Read more
Guardant Health
Technical Analysis Termsheets Terminal
Permalink
Wed, 29.04.2026       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. BofA Securities 2026 Healthcare Conference in Las Vegas, NV Fireside chat on Tuesday, May 12th at 10:40 a.m. Pacific Time William Blair 46th Annual Growth Stock Conference in Chic...
Read more
Guardant Health
Technical Analysis Termsheets Terminal
Permalink
Thu, 16.04.2026       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2026 after market close on Thursday, May 7, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast...
Read more
Guardant Health
Technical Analysis Termsheets Terminal
Permalink
Mon, 30.03.2026       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that real-world evidence generated from Guardant’s InfinityAI contributed to the recent approval of ENHERTU® (trastuzumab deruxtecan), developed and commercialized by Daiichi Sankyo (TSE:4568) in Japan, for the treatment of patients with HER2-positive (HER2 [...
Read more
Guardant Health
Technical Analysis Termsheets Terminal
Permalink
Tue, 24.03.2026       Guardant Health
US40131M1099

Combination of high quality, variable-rich, curated EHR data with genomics enhances understanding of the patient journey and aids in therapy development SAN FRANCISCO, March 24, 2026 /PRNewswire/ -- Verana Health®, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data (RWD), has announced...
Read more
Guardant Health
Technical Analysis Termsheets Terminal
Permalink
Wed, 18.03.2026       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present 28 abstracts, including 3 oral sessions, showcasing advances in methylation-based tumor classification and liquid biopsy technology at the American Association for Cancer Research (AACR) Annual Meeting i...
Read more
Guardant Health
Technical Analysis Termsheets Terminal
Permalink
Mon, 16.03.2026       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of the Shield™ multi-cancer detection (MCD) laboratory developed test (LDT) in multiple markets in Asia. The Shield MCD test is a methylation-based blood test for the detection of multiple cancer types including bladder, colorectal, breast, prostat...
Read more
Guardant Health
Technical Analysis Termsheets Terminal
Permalink
Mon, 16.03.2026       Guardant Health
US40131M1099

First insurer in Asia to bring the innovative blood-based multi‑cancer screening solution to Hong Kong, Singapore, and the Philippines TSX/NYSE/PSE: MFC     SEHK: 945 HONG KONG, SINGAPORE, and MANILA, Philippines, March 16, 2026 /PRNewswire/ -- Manulife today announced an exclusive partnership with Guardant Health, Inc. (Nasda...
Read more
Guardant Health
Technical Analysis Termsheets Terminal
Permalink
Mon, 16.03.2026       Guardant Health
US40131M1099

First insurer in Asia to bring the innovative blood-based multi‑cancer screening solution to Hong Kong, Singapore, and the PhilippinesTSX/NYSE/PSE: MFC     SEHK: 945HONG KONG, SINGAPORE, and MANILA, Philippines, March 16, 2026 /PRNewswire/ -- Manulife today announced an exclusive partnership with Guardant Health, Inc. (Nasdaq: GH), a leading preci...
Read more
Guardant Health
Technical Analysis Termsheets Terminal
Permalink
Fri, 13.03.2026       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the results of a new national survey conducted on its behalf by The Harris Poll with findings demonstrating that more than 9 out of 10 Americans ages 45 and over believe in ensuring broader coverage for blood-based colorectal cancer (CRC) screening, including...
Read more
Guardant Health
Technical Analysis Termsheets Terminal
Permalink
Tue, 10.03.2026       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the Shield™ by Guardant blood-based screening test is now widely accessible for physician order through the nationwide connectivity of Quest Diagnostics, equipping clinicians with access to blood-based screening innovation for colorectal cancer (CRC) thr...
Read more
Guardant Health
Technical Analysis Termsheets Terminal
Permalink
Wed, 04.03.2026       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of Shield Across America, a historic coast-to-coast mobile screening tour bringing Shield, the first and only FDA-approved blood test as a primary colorectal cancer (CRC) screening option and recommended in national guidelines, directly to over 100...
Read more
Guardant Health
Technical Analysis Termsheets Terminal
Permalink
Tue, 03.03.2026       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its partnership with actor and cancer advocate Patrick Dempsey to increase awareness about colorectal cancer (CRC) screening and the Shield® blood test. Approved by the U.S. Food and Drug Administration (FDA) in 2024 and recommended in national guidelines, Sh...
Read more
Guardant Health
Technical Analysis Termsheets Terminal
Permalink
Fri, 27.02.2026       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 23, 2026, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted stock units (“RSUs”) representing 41,852 shares of its common stock to 88 new non-executive employees and one non-qualified stock option...
Read more
Guardant Health
Technical Analysis Termsheets Terminal
Permalink
Thu, 19.02.2026       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights For the three-month period ended December 31, 2025, as compared to the same period of 2024: Reported total revenue of $281.3 million, an in...
Read more
Guardant Health
Technical Analysis Termsheets Terminal
Permalink
Thu, 12.02.2026       Guardant Health
US40131M1099

Patient and Public Health Groups Invited to Apply for Up to 100 Shield Colorectal Cancer Blood Tests to Support Community Screening Events and Educational Outreach in MarchPALO ALTO, Calif., Feb. 12, 2026 /PRNewswire/ -- Ahead of Colorectal Cancer (CRC) Awareness Month in March, Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology comp...
Read more
Guardant Health
Technical Analysis Termsheets Terminal
Permalink
Tue, 03.02.2026       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, UT Hosting 1x1 meetings on Tuesday, February 10th TD Cowen 46th Annual Health...
Read more
Guardant Health
Technical Analysis Termsheets Terminal
Permalink
Mon, 02.02.2026       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company and research collaborators at Mayo Clinic and the Alliance for Clinical Trials in Oncology today announced publication of the largest study to date evaluating circulating tumor DNA (ctDNA) for MRD detection in patients with resected stage III colon cancer after surgery and be...
Read more
Guardant Health
Technical Analysis Termsheets Terminal
Permalink
Thu, 29.01.2026       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 2025 after market close on Thursday, February 19, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live...
Read more
Guardant Health
Technical Analysis Termsheets Terminal
Permalink
Thu, 22.01.2026       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® CDx as a companion diagnostic to identify patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who may benefit from treatment with BRAFTOVI® (encorafenib) in combination...
Read more
Guardant Health
Technical Analysis Termsheets Terminal
Permalink
Mon, 19.01.2026       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a multi-year collaboration with Merck, known as MSD outside the United States and Canada, to support the development and commercialization of Merck’s oncology portfolio using the Guardant Infinity™ Smart platform. Under the multi-year collaboration agreemen...
Read more
Guardant Health
Technical Analysis Termsheets Terminal
Permalink
Sun, 11.01.2026       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced preliminary, unaudited results for the quarter and full year ended December 31, 2025. Fourth quarter 2025 preliminary unaudited financial results For the three-month period ended December 31, 2025, as compared to the same period of 2024: Total revenue...
Read more
Guardant Health
Technical Analysis Termsheets Terminal
Permalink
Thu, 08.01.2026       Guardant Health
US40131M1099

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer screening (CRC) is now covered for active-duty service members and their families through TRICARE, the U.S. military’s health insurance coverage, with no copay for average-risk individuals ages 45 and older. Shiel...
Read more
Guardant Health
Technical Analysis Termsheets Terminal
Permalink